Government-Owned Inventions; Availability for Licensing, 45229-45231 [E8-17812]
Download as PDF
<![CDATA[
Federal Register / Vol. 73, No. 150 / Monday, August 4, 2008 / Notices
Frequency of response: Applicants may
submit applications for published
receipt dates. If awarded, annual
progress is reported and trainees may be
appointed or reappointed. Affected
Public: Individuals or Households;
Business or other for-profit; Not-forprofit institutions; Federal Government;
and State, Local or Tribal Government.
Type of Respondents: Adult scientific
trainees and professionals. The annual
reporting burden is as follows:
Estimated Number of Respondents:
34,454; Estimated Number of Responses
per Respondent: 1; Average Burden
Hours per Response: 4.1; and Estimated
Total Annual Burden Hours Requested:
142,301. The annualized cost to
respondents is estimated at: $4,980,535.
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
information is necessary for the proper
performance of the function of the
agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of the
collection of information on those who
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
Direct Comments to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time should be sent via e-mail to
OIRA_submission@omb.eop.gov or by
fax to 202–395–6974, Attention: Desk
Officer for NIH. To request more
information on the proposed project or
to obtain a copy of the data collection
plans and instruments, contact Ms.
Mikia Currie, Project Clearance Branch,
Office of Policy for Extramural Research
Administration, NIH, Rockledge 1
Building, Suite 350, 6705 Rockledge
Drive, Bethesda, MD 20892–7974, or
call non-toll-free number (301) 435–
0941, or e-mail your request, including
your address to: curriem@od.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30 days of the date of
this publication.
Dated: July 24, 2008.
Pam Gilden,
Division of Grants Policy, Office of Policy
for Extramural Research Administration,
Office of Extramural Research, National
Institutes of Health.
[FR Doc. E8–17727 Filed 8–1–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
SUPPLEMENTARY INFORMATION:
45229
Antibodies and Antisera Recognizing
Members of the ArfGap Family of
Proteins
Description of Technology
The technology involves antibodies
and antisera that recognize members of
the ArfGap protein family, including the
following proteins:
• ACAP1, which is related to ASAP1,
a putative oncogene that regulates
cancer cell invasion into normal tissues.
ACAP1 regulates integrins, which are
critical for cell movement associated
with cancer cell invasion and is a target
of the oncogene Akt.
• ACAP2, which is related to ASAP1,
a putative oncogene that regulates
cancer cell invasion into normal tissues.
• AGAP2 (also known as PIKE–A),
ASAP1 (also called AMAP1 and DDEFl),
and ASAP3 all exhibit elevated
expression levels in cancer cells
compared to non-transformed cells and
as putative oncogenes have been
implicated as regulators of cancer cell
invasion into normal tissues and
contributors to brain, eye and breast,
and liver cancers, respectively.
• ARAP1 (also called Centaurin Delta
2), which has been implicated as a
regulator of epidermal growth factor
receptor, which plays important roles in
several malignancies.
• ARAP2 (also called Centaurin Delta
1), GIT1 and GIT2; all three of which
have been implicated as regulators of
cell migration required for cancer cell
invasion into normal tissues and
metastasis.
• ARAP3, a target of the Src
oncogene, has been implicated as a
regulator of cell movement and
signaling.
• ArfGAP1, which is critical to cell
function, including protein trafficking.
• ASAP2 (also known as PAG3 or as
Pap in the 1999 Molecular and Cellular
Biology publication), is highly related to
ASAP1, which has been implicated as a
regulator of cancer cell invasion into
normal tissues.
The table below summarizes the
antibodies and antisera available against
different ArfGap proteins. Each material
has been raised or generated to the
peptide sequence listed.
ANTIBODIES AND ANTISERA RECOGNIZING ARFGAP PROTEINS
pwalker on PROD1PC71 with NOTICES
ArfGap member
Antibody/serum ID (Alt.
Name)
Antibody
source
Peptide sequence (ID)
ACAP1 ..........
ACAP2 ..........
AGAP2 ..........
1241 (Arf6-specific GAP) .......
1288 ........................................
4569, 4571 .............................
Rabbit ...........
Rabbit ...........
Rabbit ...........
ARAP1 ..........
1153 ........................................
Rabbit ...........
RPRGQPPVPPKPSIR(556) ....................................................
REKGDESEKLDKKSS(365) ....................................................
ERVDDPELQDSI and PLSREPPPSPMVKKQ .......................
(483) .....................................................................................
SLIPLRGSENEMRRSV ...........................................................
VerDate Aug<31>2005
16:50 Aug 01, 2008
Jkt 214001
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
E:\FR\FM\04AUN1.SGM
04AUN1
HHS Ref. No.
E–244–2008/0
E–242–2008/0
E–222–2008/0
E–220–2008/0
45230
Federal Register / Vol. 73, No. 150 / Monday, August 4, 2008 / Notices
ANTIBODIES AND ANTISERA RECOGNIZING ARFGAP PROTEINS—Continued
ArfGap member
Antibody/serum ID (Alt.
Name)
Antibody
source
Peptide sequence (ID)
ARAP2 ..........
1185, 1187 .............................
Rabbit ...........
E–220–2008/1
ARAP3 ..........
Rabbit ...........
ArfGAP1 .......
862, 863, 864, 865 (CENTD3/
DRAG1).
870 ..........................................
RSRTLPKELQDEQILK ............................................................
(1689) and ANVHKTKKNDDPSKDY ...................................
DKDPPFPKGVIPLTAIE and EPVYEEPVYEEVGAFPE .........
E–243–2008/0
ASAP1 ..........
642, 645, 551, 553 .................
Rabbit ...........
ASAP1a ........
574 ..........................................
Rabbit ...........
ASAP1 ..........
.................................................
Mouse ..........
ASAP2 ..........
1267, 4574, 4575, 578 ...........
Rabbit ...........
ASAP3 ..........
Anti-ASAP3 (DDEFL1/UPLC1/
ACAP4).
.................................................
.................................................
Rabbit ...........
EWSLESSPAQNWTPPQP .....................................................
(123) .....................................................................................
VELAPKPQVGELPPKPG (962), DQDRTALQKVKKSVAC,
and murine protein residues 325–725; 440–724.
LSKKPPPPPPGHKRTL ..........................................................
(837) .....................................................................................
VELAPKPQVGELPPKPG .......................................................
(962) .....................................................................................
DEKLQPSPNRREDRP(706) and human protein fragment of
the PH, Arf GAP and Ankyrin repeat domains.
WVISTEPGSDSEEDEEKR .....................................................
Rabbit ...........
Rabbit ...........
LRQPPGPVPTPPLPSER and RKTVPPEPGAPVDF .............
RSSEVCADCSGPDPS and KVNNNLSDELRIMQKK .............
GIT1 ..............
GIT2 ..............
Applications
• Immunoblotting and other
procedures to identify the ArfGap
proteins in cells and tissues;
• Identifying tumors, such as those
found in brain, breast, eye and liver
cancers, based on protein expression
levels;
• Examining the invasive behavior of
tumor cells.
Development Status
The antibodies and antisera have been
raised or generated to the particular
peptide sequence given in the table
above. These are available as Research
Tools.
Inventors
Paul A. Randazzo et al. (NCI).
pwalker on PROD1PC71 with NOTICES
Relevant Publications
These antibodies and antisera are
further described in the following
research articles:
1. Andreev J, Simon JP, Sabatini DD,
Kam J, Plowman G, Randazzo PA,
Schlessinger J. Identification of a new
Pyk2 target protein with Arf-GAP
activity. Mol Cell Biol. 1999
Mar;19(3):2338–2350.
2. Bharti S, Inoue H, Bharti K, Hirsch
DS, Nie Z, Yoon HY, Artym V,
Yamada KM, Mueller SC, Barr VA,
Randazzo PA. Src-dependent
phosphorylation of ASAP1 regulates
podosomes. Mol Cell Biol. 2007
Dec;27(23):8271–8283.
3. Dai J, Li J, Bos E, Porcionatto M,
Premont RT, Bourgoin S, Peters PJ,
Hsu VW. ACAP1 promotes endocytic
recycling by recognizing recycling
sorting signals. Dev Cell. 2004
Nov;7(5):771–776.
VerDate Aug<31>2005
16:50 Aug 01, 2008
Jkt 214001
Rabbit ...........
4. Ha VL et al. ASAP3 is a focal
adhesion-associated Arf GAP that
functions in cell migration and
invasion. J Biol Chem. 2008 May
30;283(22):14915–14926.
5. I ST, Nie Z, Stewart A, Najdovska M,
Hall NE, He H, Randazzo PA, Lock P.
ARAP3 is transiently tyrosine
phosphorylated in cells attaching to
fibronectin and inhibits cell spreading
in a RhoGAP-dependent manner. J
Cell Sci. 2004 Dec 1;117(Pt 25):6071–
6084.
6. Inoue H and Randazzo PA. Arf GAPs
and their interacting proteins. Traffic
2007 Nov;8(11):1465–1475.
7. Li J, Ballif BA, Powelka AM, Dai J,
Gygi SP, Hsu VW. Phosphorylation of
ACAP1 by Akt regulates the
stimulation-dependent recycling of
integrin beta1 to control cell
migration. Dev Cell. 2005
Nov;9(5):663–673.
8. Miura K, Jacques KM, Stauffer S,
Kubosaki A, Zhu K, Hirsch DS, Resau
J, Zheng Y, Randazzo PA. ARAP1: a
point of convergence for Arf and Rho
signaling. Mol Cell 2002 Jan;9(1):109–
119.
9. Nie Z, Fei J, Premont RT, Randazzo
PA. The Arf GAPs AGAP1 and
AGAP2 distinguish between the
adaptor protein complexes AP–1 and
AP–3. J Cell Sci. 2005 Aug 1;118(Pt
15):3555–3566.
10. Randazzo PA, Andrade J, Miura K,
Brown MT, Long YQ, Stauffer S,
Roller P, Cooper JA. The Arf GTPaseactivating protein ASAP1 regulates
the actin cytoskeleton. Proc Natl Acad
Sci USA. 2000 Apr 11;97(8):4011–
4016.
11. Liu W, Duden R, Phair RD,
Lippincott-Schwartz J. ArfGAP1
dynamics and its role in COPI coat
assembly on Golgi membranes of
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
HHS Ref. No.
E–220–2008/2
E–221–2008/0
E–221–2008/0
E–252–2008/0
E–221–2008/1
E–221–2008/2
E–245–2008/0
E–245–2008/1
living cells. J. Cell Biol. 2005 Mar
28;168(7):1053–1063.
12. Yoon MY, Miura K, Cuthbert EJ,
Davis KK, Ahvazi B, Casanova JE,
Randazzo PA. ARAP2 effects on the
actin cytoskeleton are dependent on
Arf6-specific GTPase-activatingprotein activity and binding to RhoA–
GTP. J Cell Sci. 2006 Nov 15;119(Pt
22):4650–4666.
Patent Status
Patent protection is not being pursued
for this technology.
• HHS Reference No. E–220–2008/
0—Research Tool.
• HHS Reference No. E–220–2008/
1—Research Tool.
• HHS Reference No. E–220–2008/
2—Research Tool.
• HHS Reference No. E–221–2008/
0—Research Tool.
• HHS Reference No. E–221–2008/
1—Research Tool.
• HHS Reference No. E–221–2008/
2—Research Tool.
• HHS Reference No. E–222–2008/
0—Research Tool.
• HHS Reference No. E–242–2008/
0—Research Tool.
• HHS Reference No. E–243–2008/
0—Research Tool.
• HHS Reference No. E–244–2008/
0—Research Tool.
• HHS Reference No. E–245–2008/
0—Research Tool.
• HHS Reference No. E–245–2008/
1—Research Tool.
• HHS Reference No. E–252–2008/
0—Research Tool.
Licensing Status
Available for non-exclusive biological
materials licensing only.
E:\FR\FM\04AUN1.SGM
04AUN1
Federal Register / Vol. 73, No. 150 / Monday, August 4, 2008 / Notices
Licensing Contact
Surekha Vathyam, Ph.D.; 301–435–
4076; vathyams@mail.nih.gov.
Dated: July 28, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–17812 Filed 8–1–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: The Development of Human
Therapeutics for the Treatment of
Depression
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: This notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
Part 404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
patent license to practice the inventions
embodied in U.S. Patent Application
11/137,114 entitled ‘‘Scopolamine For
The Treatment Of Depression And
Anxiety’’ [HHS Ref. E–175–2004/0–US–
01], PCT Application PCT/US2006/
019335 [HHS Ref. E–175–2004/0–PCT–
02] and all continuing applications and
foreign counterparts (Europe, Australia
and Canada), to Transcept
Pharmaceuticals, Inc., which has offices
in Pt. Richmond, CA. The patent rights
in these inventions have been assigned
to and/or exclusively licensed to the
Government of the United States of
America.
The prospective exclusive license
territory may be worldwide, and the
field of use may be limited to:
A worldwide exclusive license for the use
of scopolamine for treatment of depression,
including major depressive disorders (MDD),
wherein the administration of scopolamine is
intravenous, through the buccal membrane,
intranasal, intramuscular or through a skin
patch.
Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before
October 3, 2008, will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated exclusive license should
be directed to: David A. Lambertson,
Ph.D., Technology Licensing Specialist,
pwalker on PROD1PC71 with NOTICES
DATES:
VerDate Aug<31>2005
16:50 Aug 01, 2008
Jkt 214001
45231
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD
20852–3804; Telephone: (301) 435–
4632; Facsimile: (301) 402–0220; E-mail:
lambertsond@od.nih.gov.
DEPARTMENT OF HOMELAND
SECURITY
The
invention concerns the use of
scopolamine for the treatment of
depression, including major depressive
disorders (MDD). Although scopolamine
has been employed in the treatment of
nausea and motion sickness, the
suitability of scopolamine for treating
MDD was unrecognized prior to this
invention. Current MDD treatments can
be ineffective in large percentage of
patients and typically do not take effect
until 4 weeks after administration. In
contrast, treatment with scopolamine
has a wide-ranging and rapid effect,
suggesting it can be effective either as a
stand alone treatment or as a treatment
for patients who are unresponsive to
currently available drugs.
A Cooperative Research and
Development Agreement (CRADA) is
simultaneously being negotiated to
accompany the exclusive license
agreement. The CRADA will involve the
further development of the licensed
technology between the National
Institute of Mental Health and
Transcept.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR part 404.7. The
prospective exclusive license may be
granted unless within sixty (60) days
from the date of this published notice,
the NIH receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR part 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Applicants may also contact the
National Institute of Mental Health
regarding the CRADA opportunity.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
National Preparedness for Response
Exercise Program
SUPPLEMENTARY INFORMATION:
Dated: July 29, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E8–17817 Filed 8–1–08; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
Coast Guard
[Docket No. USCG–2008–0521]
Coast Guard, DHS.
Notice; request for public
comment.
AGENCY:
ACTION:
SUMMARY: The Coast Guard, the Pipeline
and Hazardous Materials Safety
Administration, the Environmental
Protection Agency, and the Minerals
Management Service, in concert with
representatives from various State
governments, industry, environmental
interest groups, and the general public,
developed the National Preparedness for
Response Exercise Program (PREP)
Guidelines to reflect the consensus
agreement of the entire oil spill
response community. This notice
announces the PREP 5-year exercise
cycle, 2009 through 2013, and requests
comments from the public, and requests
volunteers from industry to participate
in the scheduled PREP Area exercises.
The new schedule adjustment from 3
years to 5 years was created to align
with the Department of Homeland
Security’s National Exercise 5-year
Schedule.
Comments and related material
must reach the Docket Management
Facility on or before October 3, 2008.
ADDRESSES: You may submit comments
identified by Coast Guard docket
number USCG–2008–0521 to the Docket
Management Facility at the U.S.
Department of Transportation. To avoid
duplication, please use only one of the
following methods:
(1) Online: https://
www.regulations.gov.
(2) Mail: Docket Management Facility
(M–30), U.S. Department of
Transportation, West Building Ground
Floor, Room W12–140, 1200 New Jersey
Avenue, SE., Washington, DC 20590–
0001.
(3) Hand delivery: Same as mail
address above, between 9 a.m. and 5
p.m., Monday through Friday, except
Federal holidays. The telephone number
is 202–366–9329.
(4) Fax: 202–493–2251.
FOR FURTHER INFORMATION CONTACT: If
you have questions on this notice, or
need general information regarding the
PREP or the 5-year exercise schedule,
contact Lieutenant Shawn Essert, Office
of Contingency Exercises (CG–535), U.S.
Coast Guard, telephone 202–372–2149,
or e-mail shawn.g.essert@uscg.mil. If
DATES:
E:\FR\FM\04AUN1.SGM
04AUN1
]]>Agencies
[Federal Register Volume 73, Number 150 (Monday, August 4, 2008)]
[Notices]
[Pages 45229-45231]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-17812]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
SUPPLEMENTARY INFORMATION:
Antibodies and Antisera Recognizing Members of the ArfGap Family of
Proteins
Description of Technology
The technology involves antibodies and antisera that recognize
members of the ArfGap protein family, including the following proteins:
ACAP1, which is related to ASAP1, a putative oncogene that
regulates cancer cell invasion into normal tissues. ACAP1 regulates
integrins, which are critical for cell movement associated with cancer
cell invasion and is a target of the oncogene Akt.
ACAP2, which is related to ASAP1, a putative oncogene that
regulates cancer cell invasion into normal tissues.
AGAP2 (also known as PIKE-A), ASAP1 (also called AMAP1 and
DDEFl), and ASAP3 all exhibit elevated expression levels in cancer
cells compared to non-transformed cells and as putative oncogenes have
been implicated as regulators of cancer cell invasion into normal
tissues and contributors to brain, eye and breast, and liver cancers,
respectively.
ARAP1 (also called Centaurin Delta 2), which has been
implicated as a regulator of epidermal growth factor receptor, which
plays important roles in several malignancies.
ARAP2 (also called Centaurin Delta 1), GIT1 and GIT2; all
three of which have been implicated as regulators of cell migration
required for cancer cell invasion into normal tissues and metastasis.
ARAP3, a target of the Src oncogene, has been implicated
as a regulator of cell movement and signaling.
ArfGAP1, which is critical to cell function, including
protein trafficking.
ASAP2 (also known as PAG3 or as Pap in the 1999 Molecular
and Cellular Biology publication), is highly related to ASAP1, which
has been implicated as a regulator of cancer cell invasion into normal
tissues.
The table below summarizes the antibodies and antisera available
against different ArfGap proteins. Each material has been raised or
generated to the peptide sequence listed.
Antibodies and Antisera Recognizing ArfGap Proteins
----------------------------------------------------------------------------------------------------------------
Antibody/serum ID
ArfGap member (Alt. Name) Antibody source Peptide sequence (ID) HHS Ref. No.
----------------------------------------------------------------------------------------------------------------
ACAP1................. 1241 (Arf6-specific Rabbit............... RPRGQPPVPPKPSIR(556)..... E-244-2008/0
GAP).
ACAP2................. 1288................. Rabbit............... REKGDESEKLDKKSS(365)..... E-242-2008/0
AGAP2................. 4569, 4571........... Rabbit............... ERVDDPELQDSI and E-222-2008/0
PLSREPPPSPMVKKQ.
(483)...................
ARAP1................. 1153................. Rabbit............... SLIPLRGSENEMRRSV......... E-220-2008/0
[[Page 45230]]
ARAP2................. 1185, 1187........... Rabbit............... RSRTLPKELQDEQILK......... E-220-2008/1
(1689) and
ANVHKTKKNDDPSKDY.
ARAP3................. 862, 863, 864, 865 Rabbit............... DKDPPFPKGVIPLTAIE and E-220-2008/2
(CENTD3/DRAG1). EPVYEEPVYEEVGAFPE.
ArfGAP1............... 870.................. Rabbit............... EWSLESSPAQNWTPPQP........ E-243-2008/0
(123)...................
ASAP1................. 642, 645, 551, 553... Rabbit............... VELAPKPQVGELPPKPG (962), E-221-2008/0
DQDRTALQKVKKSVAC, and
murine protein residues
325-725; 440-724.
ASAP1a................ 574.................. Rabbit............... LSKKPPPPPPGHKRTL......... E-221-2008/0
(837)...................
ASAP1................. ..................... Mouse................ VELAPKPQVGELPPKPG........ E-252-2008/0
(962)...................
ASAP2................. 1267, 4574, 4575, 578 Rabbit............... DEKLQPSPNRREDRP(706) and E-221-2008/1
human protein fragment
of the PH, Arf GAP and
Ankyrin repeat domains.
ASAP3................. Anti-ASAP3 (DDEFL1/ Rabbit............... WVISTEPGSDSEEDEEKR....... E-221-2008/2
UPLC1/ACAP4).
GIT1.................. ..................... Rabbit............... LRQPPGPVPTPPLPSER and E-245-2008/0
RKTVPPEPGAPVDF.
GIT2.................. ..................... Rabbit............... RSSEVCADCSGPDPS and E-245-2008/1
KVNNNLSDELRIMQKK.
----------------------------------------------------------------------------------------------------------------
Applications
Immunoblotting and other procedures to identify the ArfGap
proteins in cells and tissues;
Identifying tumors, such as those found in brain, breast,
eye and liver cancers, based on protein expression levels;
Examining the invasive behavior of tumor cells.
Development Status
The antibodies and antisera have been raised or generated to the
particular peptide sequence given in the table above. These are
available as Research Tools.
Inventors
Paul A. Randazzo et al. (NCI).
Relevant Publications
These antibodies and antisera are further described in the
following research articles:
1. Andreev J, Simon JP, Sabatini DD, Kam J, Plowman G, Randazzo PA,
Schlessinger J. Identification of a new Pyk2 target protein with Arf-
GAP activity. Mol Cell Biol. 1999 Mar;19(3):2338-2350.
2. Bharti S, Inoue H, Bharti K, Hirsch DS, Nie Z, Yoon HY, Artym V,
Yamada KM, Mueller SC, Barr VA, Randazzo PA. Src-dependent
phosphorylation of ASAP1 regulates podosomes. Mol Cell Biol. 2007
Dec;27(23):8271-8283.
3. Dai J, Li J, Bos E, Porcionatto M, Premont RT, Bourgoin S, Peters
PJ, Hsu VW. ACAP1 promotes endocytic recycling by recognizing recycling
sorting signals. Dev Cell. 2004 Nov;7(5):771-776.
4. Ha VL et al. ASAP3 is a focal adhesion-associated Arf GAP that
functions in cell migration and invasion. J Biol Chem. 2008 May
30;283(22):14915-14926.
5. I ST, Nie Z, Stewart A, Najdovska M, Hall NE, He H, Randazzo PA,
Lock P. ARAP3 is transiently tyrosine phosphorylated in cells attaching
to fibronectin and inhibits cell spreading in a RhoGAP-dependent
manner. J Cell Sci. 2004 Dec 1;117(Pt 25):6071-6084.
6. Inoue H and Randazzo PA. Arf GAPs and their interacting proteins.
Traffic 2007 Nov;8(11):1465-1475.
7. Li J, Ballif BA, Powelka AM, Dai J, Gygi SP, Hsu VW. Phosphorylation
of ACAP1 by Akt regulates the stimulation-dependent recycling of
integrin beta1 to control cell migration. Dev Cell. 2005 Nov;9(5):663-
673.
8. Miura K, Jacques KM, Stauffer S, Kubosaki A, Zhu K, Hirsch DS, Resau
J, Zheng Y, Randazzo PA. ARAP1: a point of convergence for Arf and Rho
signaling. Mol Cell 2002 Jan;9(1):109-119.
9. Nie Z, Fei J, Premont RT, Randazzo PA. The Arf GAPs AGAP1 and AGAP2
distinguish between the adaptor protein complexes AP-1 and AP-3. J Cell
Sci. 2005 Aug 1;118(Pt 15):3555-3566.
10. Randazzo PA, Andrade J, Miura K, Brown MT, Long YQ, Stauffer S,
Roller P, Cooper JA. The Arf GTPase-activating protein ASAP1 regulates
the actin cytoskeleton. Proc Natl Acad Sci USA. 2000 Apr 11;97(8):4011-
4016.
11. Liu W, Duden R, Phair RD, Lippincott-Schwartz J. ArfGAP1 dynamics
and its role in COPI coat assembly on Golgi membranes of living cells.
J. Cell Biol. 2005 Mar 28;168(7):1053-1063.
12. Yoon MY, Miura K, Cuthbert EJ, Davis KK, Ahvazi B, Casanova JE,
Randazzo PA. ARAP2 effects on the actin cytoskeleton are dependent on
Arf6-specific GTPase-activating-protein activity and binding to RhoA-
GTP. J Cell Sci. 2006 Nov 15;119(Pt 22):4650-4666.
Patent Status
Patent protection is not being pursued for this technology.
HHS Reference No. E-220-2008/0--Research Tool.
HHS Reference No. E-220-2008/1--Research Tool.
HHS Reference No. E-220-2008/2--Research Tool.
HHS Reference No. E-221-2008/0--Research Tool.
HHS Reference No. E-221-2008/1--Research Tool.
HHS Reference No. E-221-2008/2--Research Tool.
HHS Reference No. E-222-2008/0--Research Tool.
HHS Reference No. E-242-2008/0--Research Tool.
HHS Reference No. E-243-2008/0--Research Tool.
HHS Reference No. E-244-2008/0--Research Tool.
HHS Reference No. E-245-2008/0--Research Tool.
HHS Reference No. E-245-2008/1--Research Tool.
HHS Reference No. E-252-2008/0--Research Tool.
Licensing Status
Available for non-exclusive biological materials licensing only.
[[Page 45231]]
Licensing Contact
Surekha Vathyam, Ph.D.; 301-435-4076; vathyams@mail.nih.gov.
Dated: July 28, 2008.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E8-17812 Filed 8-1-08; 8:45 am]
BILLING CODE 4140-01-P
